Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 18 Oct 2017 Planned End Date changed from 30 Jul 2018 to 31 Jan 2019.
- 18 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Mar 2018.
- 23 Jan 2016 Trial design presented at the 2016 Gastrointestinal Cancers Symposium